Cencora's Ameer Ali explains why trading partners' systems, not the NDC-12 deadline itself, determine whether product keeps moving through the supply chain during the transition.
|Articles|October 13, 2021
MilliporeSigma unveils new viral vector facility
Second Carlsbad location expected to double CDMO’s production capacity
Advertisement
MilliporeSigma, a life science business of Merck, has opened its second Carlsbad, CA-based facility, expanding its contract development and manufacturing organization (CDMO) footprint. According to company officials, this new $110 million, 140,000-square-foot facility will more than double MilliporeSigma’s existing capacity to support large-scale commercial and industrial manufacturing for viral gene therapy.
As mentioned earlier, this is the CDMO’s second Carlsbad facility dedicated to cell and gene therapy. There are a total of 30 cleanroom suites between both centers to support all aspects of manufacturing, ranging from small- to large-scale clinical and commercial production.
“We are continuing to invest in solving cell and gene therapy challenges in development and manufacturing, working alongside drug developers to industrialize, scale and accelerate the path to deliver therapies to patients,” notes Matthias Heinzel, member of the executive board and CEO, life science, Merck KGaA, Darmstadt, Germany.
Advertisement
Related to this article
Nine more manufacturers join the MFN program, pairing new Medicaid pricing deals with $19.6B in U.S. manufacturing investment and API reserve donations.
Cencora's Ameer Ali explains how the shift to NDC-12 is reshaping supply chain systems and why readiness still varies widely across manufacturers.
The White House said Medicaid programs in all 50 states, D.C. and Puerto Rico now receive MFN prices, with nearly $65 billion in savings over a decade.
Rebate delays could force 340B hospitals to pay upfront and wait months for credit, distorting drug spend on the books. Valerie Bandy, PharmD, of Tecsys explains the fallout.
In this week's Pharma Pulse, Arkansas independent pharmacies bring an underpayment suit against Express Scripts, Novo Nordisk taps Anthropic for AI-driven drug discovery, and Sanofi, UCB and Opella join AstraZeneca on a supply chain heat decarbonization program.
DSCSA data exchange has matured into daily operations, but the coming NDC-12 shift and a national licensure standard add new work streams before old ones are fully settled.
Liberty Dewey of Cardinal Health breaks down the NDC-12 transition timeline, the four work streams driving it and why the biggest risk sits in trading partner handoffs.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
White House Extends MFN Pricing to Every State Medicaid Program
2
Pharma Pulse: Independent Pharmacies Sue Express Scripts, Novo Taps Anthropic, Pharma Joins Clean Heat
3
How Rebate Timing Distorts a Pharmacy's 340B Books
4
Pharma Pulse: Behind the Scenes of LogiPharma USA 2026
5